HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Lindsay, A. PubMed Articles by Lindsay, A.

JournalScan

The first 150 words of the full text of this article appear below.

	INTERVENTIONAL CARDIOLOGY

 
ACUITY at 1 year
The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial showed that in patients with moderate- and high-risk acute coronary syndromes undergoing early invasive treatment, bivalirudin monotherapy gave non-inferior rates of adverse ischaemic events and decreased rates of major bleeding when compared with heparin plus glycoprotein IIb/IIIa (GP IIb/IIIa) inhibition. ACUITY enrolled 13 819 patients from 450 academic and community-based institutions in 17 countries. Patients were assigned to receive either heparin plus GP IIb/IIIa inhibitors (n = 4603), bivalirudin plus GP IIb/IIIa inhibitors (n = 4604), or bivalirudin monotherapy (n = 4612). Of these patients, 4605 were assigned to routine upstream administration of GP IIb/IIIa inhibitors, and 4602 were deferred to selective administration. The main outcome measure was a composite of death, myocardial infarction, or unplanned revascularisation for ischaemia at 1 year.

At 1 year, 15.4% of patients given heparin plus GP IIb/IIIa inhibitors had one of the composite ischaemic . . . [Full text of this article]